Therapeutic potential of SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer

Molecular Medicine

Volumn 18, Issue 1, 2012, Pages 65-75

  Fuhler, Gwenny M ^a,b   Brooks, Robert ^a   Toms, Bonnie ^c   Iyer, Sonia ^a   Gengo, Elizabeth A ^a   Park, Mi Young ^a   Gumbleton, Matthew ^a   Viernes, Dennis R ^d   Chisholm, John D ^d   Kerr, William G ^a,c  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d SYRACUSE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA AMINOCHOLESTANE; ANTINEOPLASTIC AGENT; CASPASE; ENZYME INHIBITOR; PHOSPHATIDATE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4 BISPHOSPHATE; SH2 DOMAIN CONTAINING INOSITOL 5' PHOSPHATASE 1; SH2 DOMAIN CONTAINING INOSITOL 5' PHOSPHATASE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL COUNT; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; G0 PHASE CELL CYCLE CHECKPOINT; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CHOLESTANES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, SCID; MULTIPLE MYELOMA; PHOSPHORIC MONOESTER HYDROLASES; SRC HOMOLOGY DOMAINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857013000     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00178     Document Type: Article

References (41)

1. Yuan TL, Cantley LC. (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene. 27:5497-510.
2. Kerr WG. (2011) Inhibitor and activator: dual functions for SHIP in immunity and cancer. Ann. N. Y. Acad. Sci. 1217:1-17.
3. Alkan S, Izban KF. (2002) Immunohistochemical localization of phosphorylated AKT in multiple myeloma. Blood. 99:2278-79.
4. Troxell ML, et al. (2010) High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod. Pathol. 23:27-37.
5. Dey JH, et al. (2010) Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 70:4151-62.
6. Montero JC, Lopez-Perez R, San Miguel JF, Pandiella A. (2008) Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica. 93:851-9.
7. Bunney TD, Katan M. (2010) Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat. Rev. Cancer. 10:342-52.
8. Harvey RD, Lonial S. (2007) PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol. 3:639-47.
9. Ruela-de-Sousa RR, Queiroz KC, Peppelenbosch MP, Fuhler GM. (2010) Reversible phosphoryla-tion in haematological malignancies: potential role for protein tyrosine phosphatases in treatment? Biochim. Biophys. Acta. 1806:287-303.
10. Hazen AL, et al. (2009) SHIP is required for a functional hematopoietic stem cell niche. Blood. 113:2924-33.
11. Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. (2000) Structure, function, and biology of SHIP proteins. Genes Dev. 14:505-20.
12. Scheid MP, et al. (2002) Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3,4)P2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J. Biol. Chem. 277:9027-35.
13. Ma K, Cheung SM, Marshall AJ, Duronio V. (2008) PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity. Cell Signal. 20:684-94.
14. Franke TF, Kaplan DR, Cantley LC, Toker A. (1997) Direct regulation of the Akt proto-onco-gene product by phosphatidylinositol-3,4-bispho-sphate. Science. 275:665-8.
15. Mandl A, Sarkes D, Carricaburu V, Jung V, Rameh L. (2007) Serum withdrawal-induced accumulation of phosphoinositide 3-kinase lipids in differentiating 3T3-L6 myoblasts: distinct roles for Ship2 and PTEN. Mol. Cell. Biol. 27:8098-8112.
16. Prasad NK, et al. (2008) High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival. Tumour Biol. 29:330-41.
17. Prasad NK. (1996) SHIP2 phosphoinositol phos-phatase positively regulates EGFR-Akt pathway, CXCR4 expression, and cell migration in MDA-MB-231 breast cancer cells. Int. J. Oncol. 34:97-105.
18. Jain SK, et al. (1996) PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood. 88:1542-50.
19. Brooks R, et al. (2010) SHIP1 inhibition increases immunoregulatory capacity and triggers apopto-sis of hematopoietic cancer cells. J. Immunol. 184:3582-9.
20. Gewinner C, et al. (2009) Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 16:115-25.
21. Ivetac I, et al. (2009) Regulation of PI(3)K/Akt signalling and cellular transformation by inositol polyphosphate 4-phosphatase-1. EMBO Rep. 10:487-93.
22. Fuhler GM, et al. (2004) Disturbed granulocyte macrophage-colony stimulating factor priming of phosphatidylinositol 3,4,5-trisphosphate accumulation and Rac activation in fMLP-stimulated neutrophils from patients with myelodysplasia. J. Leuk. Biol. 76:254-62.
23. Hamilton MJ, et al. (2011) Role of SHIP in cancer. Exp. Hematol. 39:2-13.
24. Artemenko Y, Gagnon A, Sorisky A. (2009) Cat-alytically inactive SHIP2 inhibits proliferation by attenuating PDGF signaling in 3T3-L1 preadipocytes. J. Cell Physiol. 218:228-36.
25. Prasad NK, Tandon M, Badve S, Snyder PW, Nakshatri H. (2008) Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis. 29:25-34.
26. Pantou D, et al. (2005) Cytogenetic manifestations of multiple myeloma heterogeneity. Genes Chromosomes Cancer. 42:44-57.
27. Ruela-de-Sousa RR, et al. (2010) Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis. 1:e19.
28. Mehrpour M, Esclatine A, Beau I, Codogno P. (2010) Overview of macroautophagy regulation in mammalian cells. Cell Res. 20:748-62.
29. Pardo R, et al. (2010) Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells. Pancreatology. 10:19-26.
30. Kabeya Y, et al. (2000) LC3, a mammalian homo-logue of yeast Apg8p, is localized in autophago-some membranes after processing. EMBO J. 19:5720-8.
31. Ueno T, et al. (2008) Loss of Pten, a tumor sup-pressor, causes the strong inhibition of au-tophagy without affecting LC3 lipidation. Au-tophagy. 4:692-700.
32. Maiso P, et al. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br. J. Haematol. 141:470-82.
33. Shi Y, et al. (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62:5027-34.
34. Kennah M, et al. (2009) Activation of SHIP via a small molecule agonist kills multiple myeloma cells. Exp. Hematol. 37:1274-83.
35. Lakhanpal GK, et al. (2009) The inositol phos-phatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis. Blood. 116:428-36.
36. Miletic AV, et al. (2010) Coordinate suppression of B cell lymphoma by PTEN and SHIP phos-phatases. J. Exp. Med. 207:2407-20.
37. Avota E, Harms H, Schreider-Schaulies S. (2006) Measles virus inducec expression of SIP110, as constitutively membrane clustered lipid phos-phatase, which inhibits T cell proliferation. Cell. Microbiol. 8:1826-39.
38. Wahle JA, et al. (2007) Inappropriate recruitment and activity by the Src homology region 2 domain-containing phosphatase 1 (SHP1) is responsible for receptor dominance in the SHIP-deficient NK cell. J. Immunol. 179:8009-15.
39. Peng Q, et al. (2010) TREM2- and DAP12-dependent activation of PI3K required DAP10 and is inhibited by SHIP1. Sci. Signal. 3:ra38.
40. Gratacap MP, Severin S, Chicanne G, Plantavid M, Payrastre B. (2008) Different roles of SHIP1 according to the cell context: the example of blood platelets. Adv. Enzyme Regul. 48:240-52.
41. Ruschmann J, et al. (2010) Tyrosine phosphoryla-tion of SHIP promotes its proteasomal degradation. Exp. Hematol. 38:392-402.